国邦医药(605507.SH)发布前三季度业绩，归母净利润6.7亿元，同比增长15.78%

Core Insights - Guobang Pharmaceutical (605507.SH) reported a revenue of 4.47 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 1.17% [1] - The net profit attributable to shareholders of the listed company reached 670 million yuan, showing a year-on-year increase of 15.78% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 619 million yuan, reflecting a year-on-year growth of 9.59% [1]